Clinical Trials Browser

Phase 1 × Hepatoblastoma × Temozolomide × Clear all

NCT04337177 2025-09-23

Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors

Phase 1 Recruiting

CNSGastrointestinalSarcoma

Medulloblastoma, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Hepatoblastoma